Approval Summary: Imatinib Mesylate for One or Three Years in the Adjuvant Treatment of Gastrointestinal Stromal Tumors

On January 31, 2012, the U.S. Food and Drug Administration granted regular approval of imatinib mesylate tablets (Gleevec®; Novartis Pharmaceuticals Corporation, East Hanover, NJ) for the adjuvant treatment of adult patients following complete gross resection of Kit(+) (CD117(+)) gastrointestinal st...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Cohen, Martin H., Johnson, John R., Justice, Robert, Pazdur, Richard
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: AlphaMed Press 2012
Konular:
Regulatory Issues: FDA
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3399657/
https://ncbi.nlm.nih.gov/pubmed/22643537
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2012-0109
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller